# McKesson (MCK) Q2 FY2027 earnings

Results filed 2026-11-04 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/mck/2027-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/927653/000092765326000279/0000927653-26-000279-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

McKesson deepened its push into specialty and oncology care, extending its CVS Health distribution deal through June 2032 and agreeing to a roughly 49% stake in Option Care Health.

McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032. Growth came from specialty products sold to health systems and strategic accounts, and from provider solutions and specialty distribution in Oncology & Multispecialty. Prescription Technology Solutions grew on third-party logistics and access solutions, though hub dispensing contributed less. In Medical-Surgical Solutions, a weaker product mix in ambulatory care held back profit. PRISM Vision Group added Spectrum Vision Partners, bringing its network to more than 350 providers.
Management is steering toward complex specialty therapies, community-based care and biopharma services. It signed a deal to invest about $1.4 billion for roughly 49% of Option Care Health and completed the Precision Medicine Group acquisition. It is also pursuing a separation of Medical-Surgical Solutions. The main risk is execution: the Option Care Health deal needs stockholder and regulatory approvals, and the separation and acquisitions may not deliver the intended benefits or hit the planned timelines.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $111.0 billion | up 8% from a year ago | GAAP |
| Net income attributable to McKesson | $1,218 | up 10% from a year ago | GAAP |
| Diluted EPS | $10.44 | up $1.52 from a year ago | GAAP |
| Adjusted diluted EPS | $11.68 | up 18% from a year ago | non-GAAP |
| Operating income | 1,604 | up 14% from a year ago | GAAP |
| Operating cash flow | $3.1 billion |  | GAAP |
| Free cash flow | $2.9 billion |  | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| North American Pharmaceutical revenue | $91.4 billion | up 6% |
| Oncology & Multispecialty revenue | $15.0 billion | up 24% |
| Prescription Technology Solutions revenue | $1.5 billion | up 10% |
| Medical-Surgical Solutions revenue | $3.1 billion | up 5% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted EPS | fiscal 2027 | $45.60 to $46.40 |
| Revenue growth | fiscal 2027 | 6% to 10% growth |
| Effective tax rate | fiscal 2027 | 18% to 19% |
| Free cash flow | fiscal 2027 | $4.5 to $4.9 billion |

## Key takeaways

1. **CVS Health distribution partnership extended to 2032** McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. This secures a long-running anchor customer relationship.
2. **McKesson is taking a 49% stake in Option Care Health** It signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health. The deal targets complex specialty therapies and community-based care, but still needs stockholder and regulatory approvals.
3. **Precision Medicine Group acquisition expands biopharma services** McKesson completed the acquisition of Precision Medicine Group on November 2, 2026. The company calls it a milestone for its oncology, multispecialty and biopharma services strategy.
4. **Oncology & Multispecialty is the fastest-growing segment** Segment revenue rose 24% on provider solutions and specialty distribution, and management lifted full-year revenue growth expectations to 20.0% to 24.0%. Management says it is making focused investments to accelerate this and biopharma services.
5. **Medical-Surgical separation proceeds amid ambulatory mix pressure** McKesson is planning to separate Medical-Surgical Solutions, in which Apollo Funds acquired about a 13% minority stake. Segment profit fell 10% as ambulatory care mix weakened, partly offset by extended care.

## Questions

**What is McKesson's strategic deal with Option Care Health?** McKesson agreed to invest about $1.4 billion for roughly 49% of Option Care Health, supporting complex specialty therapies and community-based care. It needs Option Care Health stockholder approval and regulatory approvals.
**What happened with McKesson's CVS Health relationship?** McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
**What is driving growth in McKesson's oncology business?** Oncology & Multispecialty revenue rose 24% on growth in provider solutions and specialty distribution. McKesson also completed the Precision Medicine Group acquisition to advance oncology, multispecialty and biopharma services.
**What is happening to Medical-Surgical Solutions?** McKesson plans to separate it into an independent company, and Apollo Funds acquired about a 13% minority stake. Revenue grew 5%, but adjusted profit fell 10% on weaker ambulatory care mix.
**How did McKesson raise its full-year outlook?** It raised fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00, and lifted its revenue and operating profit growth ranges. Its segment outlooks for North American Pharmaceutical and Oncology & Multispecialty were also raised.

## Slides and investor documents

- [Presentation](https://s24.q4cdn.com/128197368/files/content_files/MCK-Q2-FY27-Presentation_FINAL.pdf) (Slide deck)
- [Transcript](https://s24.q4cdn.com/128197368/files/content_files/261104-MCK-Q2FY27-Earnings-Call-Transcript.pdf) (Company's official transcript)
- [Webcast](https://events.q4inc.com/attendee/211506614) (Webcast replay)
- [Release](https://s24.q4cdn.com/128197368/files/content_files/MCK-Q2-FY27-Earnings-Release_FINAL.pdf) (Document)
- [10-Q](https://s24.q4cdn.com/128197368/files/content_files/MCK_10Q_9-30-2026-FINAL.pdf) (Document)

